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BACKGROUND: Multiparametric MRI localizes cancer in the prostate, allowing for MRI guided biopsy (MRI-GB) 43 alongside
transrectal ultrasound-guided systematic biopsy (TRUS-GB). Three MRI-GB approaches exist; visual estimation (COG-TB); fusion
software-assisted (FUS-TB) and MRI ‘in-bore’ biopsy (IB-TB). It is unknown whether any of these are superior.We conducted a
systematic review and meta-analysis to address three questions. First, whether MRI-GB is superior to TRUS-GB at detecting clinically
significant PCa (csPCa). Second, whether MRI-GB is superior to TRUS-GB at avoiding detection of insignificant PCa. Third, whether
any MRI-GB strategy is superior at detecting csPCa.
METHODS: A systematic literature review from 2015 to 2019 was performed in accordance with the START recommendations.
Studies reporting PCa detection rates, employing MRI-GB and TRUS-GB were included and evaluated using the QUADAS-2 checklist.
1553 studies were found, of which 43 were included in the meta-analysis.
RESULTS: For csPCa, MRI-GB was superior in detection to TRUS-GB (0.83 vs. 0.63 [p= 0.02]). MRI-GB was superior in detection to
TRUS-GB at avoiding detection of insignificant PCa. No MRI-GB technique was superior at detecting csPCa (IB-TB 0.87; COG TB 0.81;
FUS-TB 0.81, [p= 0.55]). There was significant heterogeneity observed between the included studies.
CONCLUSIONS: In patients with suspected PCa on MRI, MRI-GB offers superior rates of csPCa detection and reduces detection of
insignificant PCa compared to TRUS-GB. No individual MRI-GB technique was found to be better in csPCa detection. Prospective
adequately powered randomized controlled trials are required.
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INTRODUCTION
Prostate cancer (PCa) is suspected after either an abnormal digital
rectal examination (DRE) or raised prostate-specific antigen (PSA)
test, or both. Once suspected, PCa requires tissue confirmation.
Traditionally the method to achieve this is the systematic
transrectal, ultrasound-guided prostate biopsy (TRUS-GB). The
introduction of multiparametric magnetic resonance imaging
(mpMRI) allows the identification of discrete areas of abnormal
tissue that have a higher likelihood for harbouring clinically
significant prostate cancer (csPCa). Thus, this confers a higher
sensitivity than TRUS-biopsy alone, approximately 87% to 93%,
depending on the definition of csPCa [1]. Current guidance now
recommends mpMRI to be carried out prior to the first biopsy [2].
Its use prior to biopsy has grown rapidly, to near 100% in the UK
[3]. The ability of mpMRI to localize disease in the prostate allows
for targeted or guided biopsy (MRI-GB).
Alongside the proliferation in MRI use pre-biopsy, there is
significant interest in MRI-GB [4]. For instance, there was a 20-fold
increase in the use of MRI-GB in the United States in recent years [4].
Currently, there is variation in how MRI-GB is performed. Three major
technical approaches to MRI-GB are generally employed. First, visual
estimation or cognitive targeting (COG-TB) in which a region of
interest (ROI) is identified prior to biopsy and the biopsy operator
estimates where it might be on an ultrasound image. Second,
software-assisted fusion (FUS-TB) involves identifying and contour-
ing ROIs on MR-images before biopsy and overlaying these with the
prostate contours on ultrasound images during the biopsy
procedure. This can be elastic (deformable registration to reflect
deformation of the prostate) or rigid (an overlay of MRI to ultrasound
images with some adjustment of rotation). Last, in-bore biopsy (IB-
TB) (or in-gantry) involves performing the biopsy in the MRI scanner,
guided by MR imaging taken immediately after each needle
placement.
There is currently no consensus on whether any of these
approaches is superior in terms of cancer detection. Thus, we
conducted a systematic review and meta-analysis to address first,
whether MRI-GB is superior to TRUS-GB at detecting clinically
significant PCa (csPCa). Second, if MRI-GB is better at not detecting
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insignificant PCa, and third if any of the three MRI-GB strategies is
superior at detecting csPCa.
PATIENTS AND METHODS
Search strategy
The current systematic review and meta-analysis aimed to update
the results published by Wegelin et al., 2017 [5] and followed the
guidelines suggested by the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement [6]. We
employed the identical search strategy, using the keywords
“Prostate OR Prostatic Neoplasm” AND “Biopsy” AND “Magnetic
Resonance Imaging OR Image-Guided Biopsy”. The search was
performed in PubMed, Embase, and CENTRAL databases with the
language restricted to English. As the review by Wegelin et al. [6]
included studies published before 15/12/2015, the time frame was
restricted to 15/12/2015 to 29/07/2019. The review was registered
on PROSPERO (CRD42020179508). All references were imported in
‘Zotero’ reference manager.
Study selection
For the purposes of this meta-analysis, we included studies
reporting PCa detection rates among patients at risk of PCa
according to their clinical parameters, of IB-TB, or FUS-TB, or COG-
TB alongside TRUSGB. The exclusion criteria were: inclusion of
patients with previously diagnosed PCa, on active surveillance, or
mixed populations where this group were not reported on
separately. We also excluded studies if data for patients biopsy
status was not reported, or, if a previous negative biopsy
population was included, we excluded studies where data for
with the population no or at least one negative prior biopsy were
not separately reported upon. Finally, we excluded studies if the
MRI acquisition was not in accordance with the 2012 ESUR
guidelines [7], or if studies used alternative targeted biopsy
strategies such as multiparametric ultrasound.
Quality assessment
The methodological quality of the studies was evaluated using the
Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2)
tool [8]. The assessment was performed by a single reviewer (AP)
and checked by a second (HUA). QUADAS-2 is a tool recom-
mended for use in systematic reviews to evaluate the risk of bias
and the applicability of primary diagnostic accuracy studies [8].
Data extraction
The initial data extraction was performed by a single reviewer (AP)
in accordance with the START recommendations [9] and double-
checked by a second (HUA). Data collected were: the recruitment
method (clinical parameters); investigated population character-
istics and sample size; the method of MRI acquisition and
evaluation; MRI findings and/or PI-RADS score; the threshold for
MRI positivity; biopsy method; whether the comparison between
these two methods was made; the definition of csPCa and finally
the detection rates of csPCa, and clinically insignificant PCa per
patient and per core, where available.
Data analysis
The analysis was conducted to answer our three stated aims. For
this, we first focused only on studies that reported detection rates
with both MRI-GB and TRUS-GB. Therefore, the final sample size of
the study population refers to the number of patients that
underwent both techniques. We calculated the effect sizes with
their corresponding measures of variation prior to performing the
meta-analysis.
We combined the data of all studies that reported employing
any type of MRI-GB and compared it with TRUS-GB. It was
obligatory that the studies reported results of both TRUS-GB and
MRI-GB separately. The main accuracy measure – cancer detection
rate (CDR) - was calculated by dividing the number of patients
with detected cancer by TRUS-GB (or MRI-GB), with the total
number of patients who were detected with cancer by the
combination of TRUS-GB and MRI-GB. Relative CDR was expressed
as the relative ratio between the CDR of MRI-GB and TRUS-GB. The
standard error of each of the accuracy statistics was obtained by
employing the formula for the standard error of a relative risk
without taking the paired nature into account because not all
studies reported their data in a paired format [10].
Superiority of clinically insignificant PCa detection was deter-
mined by comparison of the diagnostic yield (the likelihood that
the biopsy procedure provides such a diagnosis) of each
approach. In this respect, a lower number is advantageous and
therefore the technique was regarded as ‘superior’. The yield of
detecting clinically insignificant PCa (defined by each included
study) was calculated by dividing the number of patients with
insignificant PCa (the number of patients with any PCa minus the
number of patients with csPCa) with the total number of patients
that underwent biopsy. The relative yields were calculated by
dividing the yield of MRI-GB with the yield of TRUS-GB. We pooled
the estimates by conducting random-effects meta-analysis on
precalculated effect sizes with metagen function of the meta
package (R studio Version1.2.1335), using the generic inverse
variance method and Sidik-Jonkman as a between-study-variance
estimator. We assessed the between-study heterogeneity with
Cochrane’s Q and I2 tests [11, 12]. I2 > 50% with p < 0.05 indicates
significant heterogeneity. All analyses were done for csPCa and
insignificant PCa detection rates. Publication bias was explored by
inspecting the funnel plot and by employing Eggar’s test.
To answer the third review question, we used the accuracy
measurements we defined above and focused on studies that
reported one of the MRI-GB techniques (IB-TB or FUS-TB or COG-
TB). The within-study variances were calculated based on the
exact binomial distribution. The differences in sensitivity of the
three techniques was compared by conducting the mixed
subgroup analysis with the use of subgroup.analysis.mixed.effects
function (dmetar package).
We conducted two additional subgroup analyses––one based
on the methodological quality and the other based on prior
biopsy history. The former pooled the effect sizes only from the
studies with low risk of bias and low concerns regarding
applicability. The latter included three groups (biopsy naive,
negative biopsy and a mixed group of both types of patients). We
additionally performed a focused analysis that excluded the mixed
population group. These analyses were performed for csPCa and
clinically insignificant PCa detection rates. The extracted data were
computed and pre-calculated in Microsoft Excel, version 2010,
while the meta-analyses were performed in R studio Version
1.2.1335 (Boston, MA, USA).
RESULTS
Search and selection
The systematic search of the three databases yielded a total of
1553 articles after removing 456 duplicates. We identified 40 new
studies that assessed the diagnostic accuracy of some of the three
MRI-GB techniques. Out of the identified 40 studies, 14 either did
not compare the PCa detection rates between MRI-GB and TRUS-
GB, or did not perform these comparisons in the same population
of patients, thus they were not included in the meta-analysis. Of
the remaining 26 studies, six did not report any information about
the biopsy status of the study population, leaving 20 studies that
were merged with the studies from the systematic review by
Wegelin et al. [5]. The previous systematic review included 23/
43 studies included in their meta-analysis [5] Merging new studies
with those 23 from the previously published meta-analysis [5]
provided a total of 43, including 8456 men, were finally included
in our meta-analysis (Supplementary Table 1). The complete
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selection process of the studies is presented in the PRISMA flow
chart (Fig. 1). All 20 newly identified studies, containing an
additional 4675 men, were included in the meta-analysis
comparing the three MRI-GB techniques.
Quality assessment
Quality was evaluated only in studies included in the meta-
analysis (n= 43) (Supplementary Table 1). All studies were
estimated to have low risk regarding applicability to the current
review (Supplementary figure 1b). Twenty-five studies were
deemed to have a high risk of selection bias [13–55] (Supple-
mentary figure 1a).
Population
We observed high variability of study population size, character-
istics and mean PSA level in the studies included in the meta-
analysis. The sample size varied between 20 and 1003 patients,
who were aged between 59.7 and 70 years, who either had no or
at least one prior negative biopsy. The mean PSA level ranged
from 5.7 to 11.0 ng/ml. Most studies involved a patient group with
PSA < 10 ng/ml (n= 38). A 3-Tesla scanner was used in 77% of
studies (n= 33). The most commonly used MRI-GB technique was
FUS-TB (n= 31), followed by COG-TB (n= 8) and then IB-TB (n=
5). The definition of the threshold for performing targeted biopsy
differed between studies. The PI-RADS classification system was
the most frequent (n= 34), and a score of >/= 3 was the most
used cutoff. The studies varied considerably in the definition of
csPCa as well; therefore we performed the analysis depending on
the definition given in the original articles.
MRI-GB versus TRUS-GB
Does MRI-GB result in a higher CDR for clinically significant PCa
compared with TRUS-GB?. We observed a statistically significant
difference between the sensitivity of MRI-GB and TRUS-GB
techniques for csPCa, with a pooled relative CDR of 1.24 [95% CI
1.03; 1.50, p= 0.02] although with significant heterogeneity
among the studies (I2= 95.9%) (Fig. 2). The pooled CDR for MRI-
GB was 0.83 [95% CI 0.76–0.90] and for TRUS-GB 0.63 [95% CI
0.53–0.74]. Heterogeneity was highly significant––83.7% for MRI-
GB and 97.7% for TRUS-GB. We observed no significant evidence
of publication bias (p= 0.39, Supplementary Figure 2).
Does MRI-GB result in a lower CDR for insignificant PCa compared
with TRUS-GB?. MRI-GB was less likely to result in a diagnosis of
clinically insignificant PCa. The diagnostic yield for MRI-GB was
0.08 [95% CI 0.06; 0.11] (I2= 93.1%) and the yield for TRUS-GB was
0.15 [95% CI 0.12; 0.17] (I2= 92.7%). The pooled analysis showed
that MRI-GB performed significantly better (p < 0.0001) with a
pooled relative yield of 0.58 [0.46; 0.74], and moderate hetero-
geneity between the studies of 63.3% (Fig. 3). There was
significant publication bias among the studies (p= 0.003, Supple-
mentary Figure 3).
Which MRI-GB technique performed best at detecting csPCa and
avoiding detection of insignificant PCa?. We observed no
statistically significant differences between the three MRI-GB
techniques in detecting csPCa (p= 0.55) with IB-TB showing a
pooled CDR of 0.87 [95% CI 0.81–0.93], COG-TB 0.81 [95% CI
0.69–1.03] and FUS-TB 0.81 [95% CI 0.73-0.91]. There was no
statistically significant difference between the three techniques in
detecting clinically-insignificant PCa (p= 0.46); IB-TB had a pooled
yield of 0.10 [95% CI 0.03–0.31]; COG-TB 0.05 [95% CI 0.02–0.11],
and FUS-TB 0.08 [95% CI 0.06–0.11].
Subgroup analysis
Due to the high heterogeneity among the included studies, we
performed a subgroup analysis including only studies with low risk
of bias and low concerns of applicability (n= 18). This revealed a
relative pooled CDR of 1.23 (1.02; 1.47) in the detection of csPCa in
favour of MRI-GB (n= 11). The heterogeneity was high (I2=
90.4%).
The analysis also found the pooled relative CDR in detecting
csPCa trended towards higher in patients that had at least one
prior negative biopsy (1.59 [95% CI 1.16-2.16]) compared to
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Fig. 2 Cancer detection rate for csPCa. Forest plot representing
relative CDR of MRI-GB to TRUS-GB.
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biopsy-naive men (1.06 [95% CI 0.94–1.20]) although this did not
reach statistical significance (p= 0.06).
DISCUSSION
In summary, we first found a significant difference in CDR between
TRUS-GB and MRI-GB for the detection of csPCa. We also observed
considerably higher values of relative CDR after updating the analysis
with newly identified studies than those in the previously published
systematic review [5]). Third, MRI-GB detected fewer clinically
insignificant cancers. Fourth, there was no statistically significant
difference between the three techniques in CDR for csPCa.
Whilst the replacement of TRUS-GB with MRI-GB is technically
achievable, the removal of systematic biopsy from our diagnostic
pathway is controversial. This is due to concerns over missing
significant disease ‘hidden’ in areas of the prostate that appear
normal on MRI. Indeed, this analysis suggests that whilst superior,
an MRI-GB approach alone would miss 17% of cases of csPCa.
However, by comparison, TRUS-GB would miss 37% of such cases.
This is an expected finding. For example, missing 40% of csPCA is
broadly in keeping with the literature [1]. The multicentre
PRECISION trial demonstrated the superiority of MRI-GB over
TRUS-GB in terms of both detection of csPCa and of overdiagnosis
of clinically insignificant PCa [56]. However, some csPCa that is
missed by TRUS-GB is detected by MRI-GB and vice versa [57]. A
combined approach of both systematic and targeted biopsy may
be optimal, although these ‘missed’ cancers are likely to be low
volume, low grade or with small amounts of pattern 4, leading to
ongoing controversy as to their clinical importance [58].
The debate over which targeting approach is more accurate is
ongoing. None of the aforementioned approaches has proven its
superiority in a direct comparative trial. In our analysis, we did not
find any approach superior in the critical aspect of detecting
csPCa. A recently published RCT directly comparing all three
approaches found no difference in csPCa detection rates, although
the study was powered for the detection of any cancer [59]. The
literature may be limited on this topic with highly expert
practitioners conducting the COG-TB from which results are
reported. Drawing strong conclusions with regard to the presence
or absence of superiority of any technique is also challenging due
to the significant heterogeneity between included studies. We
also found evidence of publication bias in the studies reporting
detection rates of csPCa and clinically insignificant disease.
Our meta-analysis has some limitations. First, there was
significant patient selection bias in the included studies as in
general only men with suspicious MRIs were included. This does
not reflect a biopsy-naive population, arguably the most clinically
relevant patient group to which this effect applies. If men with
non-suspicious MRIs were included, it is likely the effect would be
larger [57]. It should therefore be kept in mind that these studies
all evaluate the efficacy of an mpMRI scan and a biopsy strategy.
Second, there was significant heterogeneity in the included
studies. Some variation was observed in MRI acquisition with
variance in scanner resolution, the threshold for biopsy and most
importantly, there was inconsistency in the MRI reporting
standards. However, all the studies included in the meta-analysis
followed the European Society of Genito-Urinary (ESUR) prostate
mpMRI guideline standards [7] and 34 of 43 studies used PIRADS as
their chosen reporting system. Further, there was variance in the
indications for biopsy. As we have already stated, a biopsy-naive
population is most relevant and the least biased. We included
studies with the multitude of indications that physicians face in
clinical practice in order to improve our findings’ generalizability
for the reader. Naturally, a more homogeneous group of studies is
ideal. However, if only studies with biopsy-naive populations were
included only 13 studies with 1878 patients could be included; if
only studies using PIRADS with a cutoff score of > /=3 were
included in addition to a biopsy-naïve population then only two
studies could be included in the meta-analysis.
Third, the thresholds used for csPCa varied although most used
the presence of any Gleason >/= 3+ 4 when it was reported.
Further, and more problematic, is that commonly used definitions
of csPCa are modelled from systematic biopsy data and as such
their utility in targeted biopsy has inherent challenges. For
example, targeted biopsies by design take multiple cores from a
single area of interest. Thus, when total cancer core lengths or
numbers/percentages of positive cores are used in this setting
there is a significant risk of over-estimation of risk; something we
have described as the potential Will–Rogers phenomenon [60].
Fourth, given the aforementioned drawbacks of TRUS-GB [1] we
acknowledge that its use as a reference standard for determining
the ideal MRI-GB technique is not optimal. Template mapping
biopsies would represent a better reference standard for
answering our third question. However, one should bear in mind
that a recent RCT also found no advantage to any technique [59].
Finally, there were variations in biopsy technique between
studies. For example, by the number of cores taken, or whether
TRUS-GB or MRI-GB was performed first. If the former is true then
prostatic swelling may affect diagnostic accuracy due to the
swelling altering prostatic morphology. There are also numerous
FUS-TB systems available on the market. Some use rigid fusion
systems where the MR-images simply overlay the USS images, and
some use elastic fusion systems where double contouring
accounts for prostatic deformation by the ultrasound probe. A
definitive, multi-user, multi-centre, multi-fusion platform rando-
mized controlled trial sufficiently powered for csPCa to overcome
these incorporation biases is needed.
CONCLUSIONS
In men where PCa is suspected on MRI, MRI-GB offers superior
rates of csPCa detection and significantly reduces diagnoses of
insignificant PCa compared to TRUS-GB. In terms of the superiority
of MRI-GB techniques we found no significant differences in CDR
for csPCa. More than half of the included studies were subject to
significant selection bias and thus conclusions must be tempered.
Further, in studies reporting on COG-TB, highly expert practi-
tioners performed the biopsies, possibly overstating the sensitivity
of the technique. A robust RCT design appropriately powered for
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Fig. 3 Relative yield for insignificant PCa detection. Forest plot
representing the relative yield for detecting insignificant PCa of MRI-
GB to TRUS-GB.
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CODE AVAILABILITY
Example r code used for this analysis is found in a statistical methodology paper by
Shim et al. [61]
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